A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) and Elevated Alanine Aminotransferase (ALT)
Sponsor: Southern California Institute for Research and Education
Listed as NCT03073343, this NA trial focuses on ALT and Non Insulin Dependent Diabetes and remains actively recruiting participants. Sponsored by Southern California Institute for Research and Education, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
-
Apr 2022 — Jun 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Recruiting NA
-
Oct 2018 — Apr 2020 [monthly]
Recruiting NA
-
Jun 2018 — Oct 2018 [monthly]
Recruiting NA
-
May 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Southern California Institute for Research and Education
For direct contact, visit the study record on ClinicalTrials.gov .